Samsung Biologics Strikes €1.57bn Deal for PolyPeptide
Samsung Biologics, a leading South Korean CDMO that provides integrated services from discovery to commercial production, has entered into a definitive agreement to acquire Swiss listed PolyPeptide Group in a deal valuing the company at CHF 1.46bn (€1.57bn). PolyPeptide is a Swiss based specialist contract manufacturer of peptide based active pharmaceutical ingredients used by major pharmaceutical and biotechnology firms globally.…
Alcami expands into Europe With Tjoapack acquisition
US-based CDMO Alcami Corporation has acquired Tjoapack, global contract packaging organisation specialising in primary and secondary packaging for the pharmaceutical industry. The deal represents a significant consolidation within the pharmaceutical services sector. This transaction also marks the first European expansion for the North Carolina based group. By integrating Tjoapack, Alcami is establishing a transatlantic platform that addresses the increasing demand…